| 561 | 9 | 11 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:以生物可降解材料聚乳酸-羟基乙酸共聚物(PLGA)为载体材料制备高良姜素-PLGA纳米粒(GL-PLGA NPs),并优化其处方。方法:采用改良乳化-溶剂挥发法制备纳米粒,HPLC测定高良姜素的含量。以粒径和包封率为指标,采用单因素和正交试验法优选处方,并对优化后的GL-PLGA NPs从表观形态、粒径分布、zeta电位、包封率进行质量评价。结果:高良姜素-PLGA纳米粒的最优处方条件为:有机相和水相的体积比为1∶8,聚乙烯醇浓度为1.5%,PLGA浓度为1.0%,药物浓度为0.2%。在此条件下制备的GL-PLGA NPs平均粒径为(249.00±2.44)nm,多分散系数为0.059,zeta电位为-4.86 mV,包封率为75.3%。电镜结果显示纳米粒呈球形,粒径大小均一,分散性良好。结论:该制备方法简单、稳定,可以得到粒径适宜、包封率较高的高良姜素-PLGA纳米粒。
Abstract：Objective:To make Galangin-PLGA nanoparticles(GL-PLGA NPs)using the polylactic-coglycolic acid(PLGA,a kind of biodegradable material)as the carrier material and to optimize the formulation. Methods:Nanoparticles were prepared through modified emulsification-solvent evaporation method,and the content of galangin was determined by HPLC. With particle size and entrapment efficiency as the indexes,single factor and orthogonal test were used to optimize the formulation. The surface configuration,particle size distribution,zeta potential,and entrapment efficiency of the optimized GL-PLGA NPs were evaluated. Results:The optimal prescription conditions of GL-PLGA NPs were as follows:the volume ratio of organic phase to aqueous phase was 1∶8,the concentration of polyvinyl alcohol was 1.5%,the concentration of PLGA was 1.0%,and the drug concentration was 0.2%. Under these conditions,the average particle size of GL-PLGA NPs was(249.00±2.44)nm,polydispersity index was 0.059,zeta potential was-4.86 mV,and the entrapment efficiency was 75.3%. The results of electron microscopy showed that the nanoparticles had sphericity,uniform particle size,and good dispersion. Conclusion:The preparation method is simple and stable,and GL-PLGA NPs with suitable particle size and high entrapment efficiency can be obtained through this method.
1张旭光，尹航，陈峰，等.高良姜素药理活性的研究进展[J].中国现代中药，2016,18(11):1532-1536.
2喻明洁，欧阳净，冯伟，等.高良姜抗菌作用现代研究进展[J].现代中药研究与实践，2019,33(6):82-86.
3李建梅，霍仕霞，高莉，等.不同纯度高良姜素的药代动力学比较研究[J].中国药理学通报，2012,28(9):1307-1310.
4 Song W,Yan CY,Zhou QQ,et al.Galangin potentiates human breast cancer to apoptosis induced by TRAILthrough activating AMPK[J].Biomed Pharmacother,2017,89:845-856.
5 Pareek V,Bhargava A,Bhanot V,et al.Formation and characterization of protein corona around nanoparticles:A review[J].J Nanosci Nanotechnol,2018,18(10):6653-6670.
6 Subramaniam VD,Prasad SV,Banerjee A,et al.Health hazards of nanoparticles:Understanding the toxicity mechanism of nanosized Zn O in cosmetic products[J].Drug Chemic Toxicol,2019,42(1):84-93.
7杜先华，牛欣，徐荣廷，等.良附微乳和良附丸中高良姜素药代动力学比较[J].北京中医药大学学报，2008,(4):269-272.
8 Budhian A,Siegel S,Winey K.Haloperidol-loaded PLGA nanoparticles:Systematic study of particle size and drug content[J].Int J Pharm,2007,336(2):367-375.
9梁洁，黄春燕，麦嘉妮，等.多指标综合评分法优选不同产地龙眼叶的提取工艺[J].中药材，2018,41(7):1694-1697.
10朱迪冰，赵海燕，何建丹，等.姜黄素PLGA纳米颗粒的制备及表征[J].亚太传统医药，2020,16(3):46-49.
11国家药典委员会.中华人民共和国药典：一部[S].2020年版.北京：中国医药科技出版社，2020.
12陈婷婷，李顺英，秦婷婷，等.Box-Behnken响应面法优化海藻酸钠m PEG-b-PLGA纳米粒处方工艺[J].中国药学杂志，2019,54(19):1590-1598.
13胡慧中，郑晓君，胡巧红.姜黄素-甘草次酸-PEI-PLGA纳米粒的制备及工艺优化[J].山东医药，2015,55(16):8-11.
14 Shi LL,Cao Y,Zhu XY,et al.Optimization of process variables of zanamivir-loaded solid lipid nanoparticles and the prediction of their cellular transport in caco-2 cell model[J].Int J Pharm,2015,478(1):60-69.
15寇龙发，高利芳，姚情，等.乳化溶剂挥发法制备紫杉醇PLGA纳米粒及其体外评价[J].中国药剂学杂志（网络版），2014,12(2):33-42.
16邵陇龙，甄平.乳化溶剂挥发法制备PLGA微球影响因素的研究进展[J].甘肃医药，2017,36(12):1007-1010.
17向海滨，梁求真，李新霞，等.利福喷丁/聚乳酸-羟基乙酸纳米粒的制备及处方工艺优化[J].中国医院药学杂志，2020,40(18):1950-1956.
18许浩云，谢黎崖，常迪，等.改良透析法制备Me PEG-PLGA-羟基喜树碱共聚物纳米粒[J].中国现代应用药学，2016,33(6):746-751.
基本信息:
DOI：10.13210/j.cnki.jhmu.20201120.002
中图分类号:R283.6
引用信息:
[1]陈莹子,朱蓉,孙旭怡,等.高良姜素-PLGA纳米粒的处方优化及其表征[J].海南医学院学报,2021,27(11):809-813+819.DOI:10.13210/j.cnki.jhmu.20201120.002.
基金信息:
国家自然科学基金资助项目（81660649）; 2019年海南医学院大学生创新创业训练计划项目（X201911810073）~~
2020-11-20
2020-11-20
2020-11-20